Clinical Trial Update: A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib [Phase 2]

View source ↗

Summary

A Phase 2 trial of Avutometinib (VS-6766) in combination with Defactinib is recruiting for several gynecologic cancers, including endometrial cancer, mucinous o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• High-grade Serous Ovarian Cancer
• Mucinous Ovarian Cancer

Drugs mentioned

• Avutometinib (VS-6766) (Avutometinib)
• Defactinib (defactinib)

Snippet

Sponsor: University of Oklahoma | Conditions: Endometrioid Cancer, Mucinous Ovarian Cancer | Phase 2 | Status: RECRUITING